Table 2.
Univariate and multivariate Cox regression analysis of overall survival (n=300) in diabetic patients.
| Characteristics | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95%CI) | P value | HR (95%CI) | P value | |
| DM with HbA1c>6.6 vs. DM with HbA1c ≤ 6.6 | 1.929 (1.355-2.746) | <0.001 | 1.593 (1.113-2.280) | 0.011 |
| Female vs. Male | 0.624 (0.461-0.843) | 0.002 | 1.111 (0.712-1.736) | 0.642 |
| Age>65 vs. ≤65 | 1.279 (0.943-1.735) | 0.114 | 1.138 (0.832-1.558) | 0.419 |
| Ever smoker vs. Non-smoker | 1.685 (1.263-2.248) | <0.001 | 1.392 (1.029-1.882) | 0.032 |
| With CVD vs. without CVD | 1.339 (1.005-1.785) | 0.046 | 0.895 (0.654-1.226) | 0.490 |
| BMI>24 vs. ≤24 | 1.203 (0.895-1.619) | 0.221 | 1.053 (0.758-1.463) | 0.757 |
| Stage IV vs. IIIB | 2.267 (1.654-3.108) | <0.001 | 2.674 (1.934-3.699) | <0.001 |
| EGFR wildtype vs. EGFR-mutated | 2.982 (2.202-4.038) | <0.001 | 2.970 (2.166-4.071) | <0.001 |
| Non-adenocarcinoma vs. Adenocarcinoma | 1.902 (1.403-2.578) | <0.001 | 1.278 (0.887-1.841) | 0.188 |
| First-line EGFR-TKIs vs. Non EGFR-TKIs | 0.408 (0.289-0.576) | <0.001 | 0.925 (0.573-1.493) | 0.750 |
DM, diabetes; CVD, cardiovascular disease; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitors.